Few areas of addiction treatment carry as much lingering misunderstanding as medication-assisted treatment the idea that using an FDA-approved medication to treat opioid or alcohol use disorder is somehow "replacing one addiction with another." That framing doesn't hold up against the actual research, and it keeps some people from a treatment approach with one of the stronger evidence bases available. Here's what MAT actually involves.
Medication-assisted treatment combines FDA-approved medication with counseling and behavioral therapy to treat substance use disorders primarily opioid use disorder, and separately, several medications approved for alcohol use disorder. The medication addresses the physiological aspects of dependence cravings, withdrawal, and in some cases blocking the effects of the substance entirely while therapy addresses the behavioral and psychological aspects. It's designed as a combined approach, not medication alone.
| Medication | How It Works |
|---|
| Methadone |
A full opioid agonist that reduces cravings and withdrawal without producing the same intensity of euphoria at a stable, medically managed dose. Dispensed daily through a certified opioid treatment program, with structured guidelines around monitoring and take-home privileges over time. |
| Buprenorphine |
A partial opioid agonist with a "ceiling effect" that limits its euphoric and respiratory-depressant effects even at higher doses, contributing to its comparatively lower overdose risk. Often combined with naloxone (as in Suboxone) to further deter misuse. Can be prescribed by qualified providers for take-home use, rather than requiring daily clinic visits. |
| Naltrexone |
An opioid antagonist that blocks opioid effects entirely rather than reducing cravings through agonist activity. Requires full detox before starting, since it can precipitate immediate, severe withdrawal if opioids are still present in the system. Available as a daily pill or a monthly injectable (Vivitrol). |
- Naltrexone reduces the rewarding effects of alcohol, helping reduce heavy drinking
- Acamprosate helps stabilize brain chemistry disrupted by chronic alcohol use, primarily supporting abstinence maintenance after detox
- Disulfiram produces an unpleasant physical reaction if alcohol is consumed, functioning as a deterrent rather than addressing craving directly
MAT for opioid use disorder has one of the more extensively documented evidence bases in addiction medicine. Research consistently associates MAT with reduced opioid use, improved treatment retention, and critically significantly reduced overdose mortality compared to non-medication approaches. Federal health agencies, including SAMHSA and NIDA, identify MAT as an evidence-based standard of care for opioid use disorder specifically, not an alternative or lesser option to abstinence-based treatment.
This is worth engaging with directly rather than dismissing. Physical dependence the body adapting to a substance's regular presence is not the same thing as addiction, which involves compulsive use despite harmful consequences, loss of control, and significant life disruption. Someone stabilized on a properly monitored, appropriately dosed MAT medication is not experiencing escalating use, loss of control, or the life disruption that defines active addiction the medication is functioning as intended, similar in principle to insulin managing diabetes, not as a substitute high. This distinction is well-established in addiction medicine, even though it hasn't fully reached public understanding.
This varies significantly by individual, medication, and clinical judgment. Some people use MAT for a defined period as part of a broader treatment and recovery plan; others continue longer-term, sometimes indefinitely, similar to ongoing management of other chronic health conditions. Current clinical guidance generally cautions against a fixed timeline or pressure to discontinue on a predetermined schedule the decision should be individualized and made collaboratively with a prescriber based on actual clinical stability, not an arbitrary deadline.
Increasingly, yes many residential and outpatient programs now integrate MAT directly rather than requiring abstinence-only approaches. It's worth asking any facility directly whether MAT is available and clinically supported, particularly for opioid use disorder, since some programs still operate on an abstinence-only model that may not align with current best-practice guidance for every individual's situation.
Frequently asked questions
Yes federal health agencies including SAMHSA and NIDA recognize MAT as an evidence-based standard of care for opioid use disorder, supported by extensive research on reduced overdose mortality and improved treatment retention.
No. Physical dependence on a properly monitored medication is clinically distinct from active addiction, which involves loss of control and escalating harmful use. A person stabilized on MAT is not experiencing that pattern.
It varies significantly by individual some use it for a defined treatment period, others continue longer-term. Current clinical guidance generally recommends against a fixed, predetermined timeline.
No naltrexone requires full detox first, since it can precipitate immediate and severe withdrawal if opioids are still present in the system. This is a critical distinction from methadone and buprenorphine.
Most insurance plans, including Medicaid in all states, are required to cover substance use disorder treatment at parity with medical care, which generally includes MAT specific coverage details vary by plan, so direct verification is worthwhile.
Yes naltrexone, acamprosate, and disulfiram are all FDA-approved medications for alcohol use disorder, working through different mechanisms depending on the medication.
This article was reviewed by the RehabsNearMe Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available treatment resources, government agencies, and healthcare references where applicable.
Last reviewed: August 2026
Related articles
Resources
